Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sirolimus + Lucentis in wet AMD (EMERALD)
NCT00766337Phase 2Terminated
- Sponsor
- Santen Pharmaceutical
- Start
- Dec 2008
- Primary completion
- Nov 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of sirolimus in exudative macular degeneration, sponsored by Santen Pharmaceutical. Started Dec 2008; status: terminated.
02
Drugs
sirolimus
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on NCT00766337.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00766337.